Denali Therapeutics Inc. (NASDAQ:DNLI) Receives $38.90 Consensus Target Price from Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has received a consensus rating of “Moderate Buy” from the eleven analysts that are currently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $38.90.

DNLI has been the topic of a number of recent research reports. Bank of America lifted their target price on Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday, September 4th. JPMorgan Chase & Co. cut their price objective on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Cantor Fitzgerald cut shares of Denali Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, October 7th. Citigroup lifted their target price on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Finally, Raymond James restated a “market perform” rating on shares of Denali Therapeutics in a research report on Thursday, October 10th.

Denali Therapeutics Price Performance

Shares of Denali Therapeutics stock opened at $24.50 on Thursday. Denali Therapeutics has a 1-year low of $14.56 and a 1-year high of $33.33. The business’s fifty day moving average price is $27.88 and its two-hundred day moving average price is $24.33. The company has a market capitalization of $3.53 billion, a P/E ratio of -8.88 and a beta of 1.40.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the business earned ($0.72) EPS. On average, research analysts expect that Denali Therapeutics will post -2.69 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Ryan J. Watts sold 40,000 shares of the firm’s stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $27.69, for a total transaction of $1,107,600.00. Following the completion of the transaction, the chief executive officer now directly owns 235,807 shares of the company’s stock, valued at approximately $6,529,495.83. This trade represents a 14.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Vicki L. Sato sold 1,020 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $30.00, for a total transaction of $30,600.00. Following the completion of the transaction, the director now directly owns 111,056 shares of the company’s stock, valued at $3,331,680. This trade represents a 0.91 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 86,578 shares of company stock valued at $2,474,440. Insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

A number of large investors have recently bought and sold shares of the business. MONECO Advisors LLC raised its stake in shares of Denali Therapeutics by 4.6% in the third quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock worth $265,000 after acquiring an additional 400 shares during the last quarter. Assetmark Inc. raised its position in Denali Therapeutics by 18.0% in the 3rd quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock worth $111,000 after purchasing an additional 580 shares during the last quarter. CWM LLC lifted its holdings in Denali Therapeutics by 43.6% during the 3rd quarter. CWM LLC now owns 2,153 shares of the company’s stock worth $63,000 after buying an additional 654 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Denali Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock valued at $152,000 after buying an additional 920 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Denali Therapeutics by 5.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock valued at $613,000 after buying an additional 1,372 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.